Pfizer Inc. $PFE Shares Purchased by Welch Group LLC

Welch Group LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 4.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,986,914 shares of the biopharmaceutical company’s stock after buying an additional 78,141 shares during the quarter. Pfizer makes up approximately 2.0% of Welch Group LLC’s holdings, making the stock its 27th largest holding. Welch Group LLC’s holdings in Pfizer were worth $50,627,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the stock. GKV Capital Management Co. Inc. purchased a new stake in Pfizer in the first quarter valued at approximately $27,000. Curio Wealth LLC boosted its holdings in shares of Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares during the last quarter. Bayforest Capital Ltd purchased a new stake in shares of Pfizer during the 1st quarter valued at $28,000. Harbor Asset Planning Inc. acquired a new stake in shares of Pfizer during the 2nd quarter worth $29,000. Finally, Howard Hughes Medical Institute purchased a new position in shares of Pfizer in the 2nd quarter worth $30,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $25.23 on Tuesday. The business’s 50-day simple moving average is $25.11 and its 200 day simple moving average is $24.86. The company has a market cap of $143.43 billion, a P/E ratio of 14.67 and a beta of 0.46. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of research analyst reports. HSBC reiterated a “buy” rating and issued a $29.00 target price on shares of Pfizer in a report on Wednesday, December 10th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Morgan Stanley reduced their price target on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Friday, December 12th. Finally, Citigroup began coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus price target of $28.06.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.